Download the presentation here: PDF

More documents

Recommendations

Info

And Several Recent “Specialty-Size” Success Stories $ Millions 8 350 300 250 200 150 100 Sales Ramp Up of Selected Branded Pain Meds Introduced Since 1998 (WW) 50 0 1998 EvaluatePharma 2000 2002 2004 2006 2008 2010E 2012E 2014E © Defined Health, 2009 Pain Insight Briefing Avinza Opana/Opana ER Fentora Jurnista
$ Millions But Few “Big Pharma-Size” Successes 9 Sales Ramp Up of Selected Branded Pain Meds Introduced Since 1998 (WW) 5,000 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 1998 EvaluatePharma 2000 2002 2004 2006 2008 2010E © Defined Health, 2009 Pain Insight Briefing 2012E 2014E Avinza Lyrica Opana/Opana ER Fentora Jurnista VIOXX Celebrex
Page 1 and 2: Game Changing Plays in the Pain Mar
Page 3 and 4: Our Disclaimer 3 The information in
Page 5 and 6: Everyone Hurts “Pain is whatever
Page 7: It’s A Big Market with a Few Domi
Page 11 and 12: Pain Historically: Drug Delivery ha
Page 13 and 14: It’s Getting Tougher Labopharm La
Page 15 and 16: The Risk : Reward Profile for Novel
Page 17 and 18: Current Standard of Care for Pain
Page 19 and 20: Leaving Plenty of Unmet Need to Be
Page 21 and 22: In the Meantime, Let’s Teach Old
Page 23 and 24: A Better NSAID: NicOx • Naproxcin
Page 25 and 26: A Better NSAID: NicOx 25 Company pr
Page 27 and 28: A Better NSAID: Pozen / AstraZeneca
Page 29 and 30: The First-to-Market Topical NSAIDs
Page 31 and 32: Even So, Flector is Expected To Be
Page 33 and 34: Now We Have a Patch and a Gel Volta
Page 35 and 36: The Need is Clear 35 © Defined Hea
Page 37 and 38: Progenics / Wyeth: Making Opioids M
Page 39 and 40: Adolor / Pfizer: Making Opioids Mor
Page 41 and 42: Like All Things CNS, It’s Not So
Page 43 and 44: A New, and Better Opioid from J&J /
Page 45 and 46: A New, and Better Opioid from J&J /
Page 47 and 48: Opioid Abuse Deterrence 47 © Defin
Page 49 and 50: King Pharmaceuticals: Making Big Be
Page 51 and 52: But Also Significant Hurdles • Te
Page 53 and 54: The Technologies are Not the Proble
Page 55 and 56: The Real Issue is Risk Management
Page 57 and 58: Fentanyl: Again, REMS is the Big Re
Page 59 and 60:
Lessons from Fentora 59 What the FD
Page 61 and 62:
For Some Mechanisms, the US Regulat
Page 63 and 64:
FAAH Pipeline 63 Compound SSR 10101
Page 65 and 66:
FAAH Pipeline KDS-4103, acquired by
Page 67 and 68:
Addressing the Big Problem 67 >50%
Page 69 and 70:
New MOA Challenges 69 NeuroDiscover
Page 71 and 72:
New MOA Challenges 71 The identific
Page 73 and 74:
TRPV1 • The transient receptor po
Page 75 and 76:
TRPV1: Target for Novel Analgesics
Page 77 and 78:
TRPV1 Antagonists: Hot … Too Hot
Page 79 and 80:
TRPV1 Antagonist Pipeline Compound
Page 81 and 82:
TRPV1 Antagonist Pipeline 81 Compou
Page 83 and 84:
TRPV3: Hopeful, But Too Early to Te
Page 85 and 86:
Good Phase III Data, An Accepted ND
Page 87 and 88:
Pfizer Pursuing Multiple Chronic Pa
Page 89 and 90:
Concerning, but Transient Adverse E
Page 91 and 92:
Will NGF for Pain Be Like TNF is fo
Page 93 and 94:
Repurposed anti-TNF Antibodies for
Page 95 and 96:
What’s Next for Pain? • Continu
show all

Download the presentation here: PDF

Create successful ePaper yourself

Delete template?

Save as template?